Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | NA |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | oral squamous cell carcinoma |
| ICD-0-3 | C06.9 |
| Methods | RNA-seq, qPCR, Western blot |
| Sample | OSCC SCC15 cells, TW2.6 cells, OSCC tissue and serum |
| Expression Pattern | up-regulated |
| Function Description | The lncRNA ANRIL was highly expressed in the tissues and serum of patients. The proliferation ability of the cells transfected with si-ANRIL was significantly reduced, while that of the cells transfected with ANRIL-OE was overtly increased. The apoptosis rate was (9.21?5.22)%, (22.3?1.34)%, and (13.21?6.22)% in lncRNA ANRIL-OE group, si-ANRIL group and control group, respectively. The protein expression level of the apoptotic protein active caspase-3 was lowered after the treatment with ANRIL-OE, and the key molecules of the TGF-?/ Smad pathway were notably down-regulated after inhibiting ANRIL with si-ANRIL. |
| Pubmed ID | 31364119 |
| Year | 2019 |
| Title | Effects of lncRNA ANRIL on proliferation and apoptosis of oral squamous cell carcinoma cells by regulating TGF-?/Smad pathway |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for oral squamous cell carcinoma | OMIM COSMIC |